Kane Biotech Study Links Revyve Wound Gel to 43.9% Mean Wound Area Reduction

By Public Technologies
  • Kane Biotech announced published results in the International Wound Journal evaluating revyve Antimicrobial Wound Gel alongside standard wound care.
  • The prospective observational study followed 17 adults with 28 chronic and complex wounds for up to 12 weeks.
  • Adjunctive treatment was associated with reduced wound size, improved wound bed condition and lower patient-reported pain.
  • All wounds had failed prior treatment; median wound duration before treatment was 22 months.
  • The authors called for larger, controlled studies; revyve has FDA 510(k) clearance and a Health Canada license.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040705PRIMZONEFULLFEED9869570) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.